Cassava Sciences (Cassava Sciences) 3-Year Revenue Growth Rate : 0.00% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Cassava Sciences 3-Year Revenue Growth Rate?

Cassava Sciences's Revenue per Share for the three months ended in Dec. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Cassava Sciences was 132.20% per year. The lowest was -43.70% per year. And the median was -23.15% per year.

Competitive Comparison of Cassava Sciences's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Cassava Sciences's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cassava Sciences's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cassava Sciences's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Cassava Sciences's 3-Year Revenue Growth Rate falls into.

Cassava Sciences 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Cassava Sciences (NAS:SAVA) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Cassava Sciences 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Cassava Sciences's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cassava Sciences (Cassava Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cassava Sciences Inc (NAS:SAVA) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

SAVA:Mexico PX91:Germany PX91:Germany

Address

6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731

Website

https://www.cassavasciences.com

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.

Executives

Sanford Robertson	director	ONE LETTERMAN DRIVE, BUILDING C SUITE 410, SAN FRANCISCO CA 94129
Richard Barry	director	285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Robert Christopher Cook	officer: SVP & General Counsel	6801 N. CAPITAL OF TEXAS HWY, BUILDING 1, SUITE 300, AUSTIN TX 78731
James William Kupiec	officer: Chief Clinical Dev. Officer	7801 N CAPITAL OF TEXAS HIGHWAY, SUITE 260, AUSTIN TX 78731
Eric Schoen	officer: Chief Financial Officer	7801 N. CAPITAL OF TX HWY, SUITE 260, AUSTIN TX 78731
Remi Barbier	director, 10 percent owner, officer: CEO, Chairman of the Board
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
O Donnell Michael J	director
Robert Z Gussin	director
Scannon Patrick J Md Phd	director	C/O XOMA, LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Nadav Friedmann	director, officer: Chief Scientific Officer
Sabretooth Master Fund, L.p.	10 percent owner	405 LEXINGTON AVENUE, 50TH FLOOR, NEW YORK NY 10174